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Abstract
Background: Acute low back pain is a common condition resulting in pain and disability. Current
national and international guidelines advocate general practitioner care including advice and
paracetamol (4 g daily in otherwise well adults) as the first line of care for people with acute low
back pain. Non-steroidal anti-inflammatory drugs (NSAIDs) and spinal manipulative therapy (SMT)
are advocated in many guidelines as second line management options for patients with acute low
back pain who are not recovering. No studies have explored the role of NSAIDs and/or SMT in
addition to first line management for acute low back pain. The primary aim of this study is to
investigate if NSAIDs and/or SMT in addition to general practitioner advice and paracetamol results
in shorter recovery times for patients with acute low back pain. The secondary aims of the study
are to evaluate whether the addition of SMT and/or NSAIDs influences pain, disability and global
perceived effect at 1, 2, 4 and 12 weeks after onset of therapy for patients with significant acute
low back pain.
Methods/design: This paper presents the rationale and design of a randomised controlled trial
examining the addition of NSAIDs and/or SMT in 240 people who present to their general
practitioner with significant acute low back pain.
Background
Low back pain is a common condition with lifetime prev-
alence rates reported between 59 and 84% [1]. On any
given day 12–33% of people report some back pain [1]. A
recent review on the health of Australians placed back
problems as one of the three health conditions responsi-
ble for the greatest health system expenditure [2]. Not
only is back pain common and costly to the health system
but an episode of acute low back pain can be seriously dis-
abling and distressing for the patient. In many cases the
patient cannot undertake, or is severely restricted in, nor-
mal work and home duties. While it is commonly
believed that the majority of people with acute low back
pain recover spontaneously within 4–6 weeks a recent sys-
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tematic review of the prognosis of acute low back pain [3]
did not find evidence of this. On average, people with
acute back pain experience substantial improvements in
the first month: pain and disability are reduced by 58% of
initial values and 82% of patients have returned to work.
Further but smaller improvements occur up to three
months, after which pain and disability levels remain
nearly constant.
A recent review of international guidelines [4] for the
treatment of acute non-specific low back pain showed
clear agreement on the appropriate first line of care. Each
guideline recommended that the first line of care should
be provision of advice and simple analgesic medicines.
Advice includes reassuring the patient of a favourable
prognosis, encouraging the patient to stay active and dis-
couraging bed rest. It is recommended that medication
should be taken in a time contingent manner and para-
cetamol (4 g daily) is suggested as first line choice due to
its low risk of gastrointestinal side effects in otherwise well
adults.
Each of the guidelines also recommended that if first line
management options provide insufficient pain relief then
additional therapies could be considered. However, there
is no clear agreement on what the second line manage-
ment options should include or at what time it/they
should begin. All the guidelines endorsed the appropriate
use of NSAIDs but only some guidelines (8 of 11)
endorsed spinal manipulative therapy (SMT).
Research to date has primarily addressed the issue of
whether SMT and/or NSAIDs are more efficacious than
placebo, however, this question does not reflect contem-
porary evidence-based practice in the management of low
back pain. For the practitioner following the available
guidelines the salient question is whether either of these
two treatments are effective when delivered in addition to
first line care universally endorsed in the low back pain
treatment guidelines.
The recent Australian National Health and Medical
Research Council (NHMRC) acute low back pain guide-
lines 2003 [5] conclude that there is conflicting evidence
in this patient group that spinal manipulation provides
greater short term pain relief when compared to placebo.
Subsequent to the completion of these guidelines, three
systematic reviews evaluating the role of SMT in back pain
management have been published [6-8]. Each review con-
cludes that spinal manipulation provides a greater reduc-
tion in pain and disability than inactive or ineffective
therapies, with all trials providing similar estimates for the
size and precision of the treatment effect (approximately
18 points of pain relief measured on a 0–100 point
scale;95%CI 13–24) [6].
The issue of whether spinal manipulation is more effec-
tive than placebo in patients who receive general practi-
tioner (GP) advice and paracetamol as first-line care was
not directly investigated in these systematic reviews. How-
ever, in the study by Curtis et al [9] all patients received
guideline-based care (advice and paracetamol) with half
randomised to also receive a course of spinal manipula-
tive therapy. Furthermore, Curtis et al [9] reported that a
greater proportion of the manipulative therapy group
completely recovered after the first visit compared with
the control group: 14% versus 6% (P = 0.01). Patients
who received more intense manipulative therapy (four or
more treatments) had more rapid return to functional
recovery (7.8 days) compared with those who received
less treatments (11.1 days; P = 0.02). However this study
did not include an inactive manipulation intervention
and thus it is possible that the results are influenced by
intervention bias as a result of the more frequent patient-
practitioner contact in the group who received spinal
manipulation.
The Cochrane Review on the role of NSAIDs in the man-
agement of low back pain [10] located nine studies com-
paring NSAIDs to placebo and concluded that NSAIDs
were effective for short-term symptomatic relief in
patients with acute low back pain. Furthermore, the
review concluded that there was strong evidence that var-
ious types of NSAIDs are equally effective [10]. Subse-
quent to this review one study has shown that aceclofenac
provides similar results to diclofenac [11] and another
study has suggested temporal differences in analgesia pro-
duced by diclofenac pain relief when compared to ibupro-
fen or placebo [12]. However, no studies have examined
whether the addition of NSAIDs to standard first-line care
produced greater benefit than standard first-line care
alone or whether there is an additive effect of manipula-
tive therapy and NSAIDs.
In summary, there is high quality level I evidence that
both SMT and NSAIDs are more efficacious than placebo
treatments in patients with acute low back pain who
receive no additional care. This evidence is of limited use
to GPs managing patients with acute low back pain
according to the widely accepted first line care. The most
important clinical question is whether NSAIDs and/or
spinal manipulation are effective when delivered in addi-
tion to the first line of care. At present there is no high
quality evidence for this. In 2003, the NHMRC clinical
practice guidelines for the evidence-based management of
acute low back pain identified the need for research into
the use of NSAIDs and spinal manipulative therapy and
recommended testing these interventions in well-
designed randomised controlled trials (RCTs) with 'advice
to avoid bed rest and maintain usual activities' as the
appropriate comparator [5].BMC Musculoskeletal Disorders 2005, 6:57 http://www.biomedcentral.com/1471-2474/6/57
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The primary aim of this study is to investigate whether the
addition of SMT and/or NSAIDs to GP advice and para-
cetamol results in shorter recovery times for patients with
significant acute low back pain. The secondary aims of
this study are to evaluate whether the addition of SMT
and/or NSAIDs to GP advice and paracetamol influences
pain, disability and global perceived effect at 1, 2, 4 and
12 weeks for patients with significant acute low back pain.
Methods
This randomised controlled trial will be conducted at
approximately 20 general practice clinics and 10 private
physiotherapy clinics within Sydney, Australia. Ethics
approval has been gained from the University of Sydney
Human Research Ethics Committee.
Study population
Two hundred and forty participants with a new episode of
significant acute non specific low back pain who present
to GPs will be recruited. GPs will screen potential partici-
pants to ensure they satisfy the inclusion and exclusion
criteria and will provide participants with an information
sheet. The GP will then contact one of the researchers by
phone and pass on the patient's contact details. The
researchers will then organise an appointment within two
days (excluding Sundays) to meet with the participant,
formally enrol them in the trial if eligibility is confirmed
at which time they will be randomised to a treatment arm
of the study.
Inclusion criteria
To be eligible for the trial participants must meet all of the
following criteria as assessed by the GP:
• Primary complaint of pain extending in an area between
the 12th rib and buttock crease. This may or may not be
accompanied by leg pain.
• New episode of low back pain. This is defined as an epi-
sode which was preceded by a period of at least one
month without low back pain where the participant was
not consulting a health care practitioner or continuing
with medication for their low back pain [13].
• Pain of less than six weeks duration.
• Low back pain severe enough to cause moderate pain
and moderate interference with normal work including
work outside the home and housework (as measured by
adaptations of items 7 and 8 of the SF-36).
• No known or suspected serious spinal pathology (meta-
static, inflammatory or infective diseases of the spine,
cauda equina syndrome, spinal fracture).
• No nerve root compromise evidenced by at least two of
the following (i) myotomal weakness, (ii) dermatomal or
widespread sensory loss, (iii) hypo or hyper-reflexia of the
lower limb reflexes.
• Not currently taking NSAIDs.
• Not currently receiving SMT.
• No spinal surgery within the preceding six months.
• No history of peptic ulcer.
• No allergy to aspirin.
• Not currently receiving anticoagulant therapy.
• No serious co-morbidities preventing prescription of
NSAIDs or paracetamol eg: cardiac, liver or renal failure.
• No contraindications to SMT or NSAIDs
Enrolment and baseline measures
At the first meeting with the researcher, baseline data will
be collected from the participant. This will include contact
details, personal details, outcome measures, and variables
that will be assessed as predictors of response to treat-
ment. Contact details for both the participant and a friend
or relative who does not live with them will be collected
to optimise follow up rates. Personal details recorded will
include age, length of time symptoms have been present
and the number of previous episodes of low back pain.
The following baseline measures of outcome will be
recorded:
• Numerical pain rating scale on a 0–10 scale [14];
• A back specific disability scale (Roland Morris Disability
Scale) [15];
• A patient specific measure of disability (Patient Specific
Functional Scale)[16];
Treatment allocation
Immediately after completing baseline measures partici-
pants will be allocated into treatment groups. Prior to the
start of the study a researcher not involved in data collec-
tion or analysis will develop a randomisation schedule
and produce consecutively numbered sealed opaque
envelopes containing each participant's allocation. Ran-
domisation will be performed using randomly permuted
blocks of 4, 8 and 12. The researcher will select the next
numerical randomisation envelope and open it. This
envelope will contain a plastic bottle with the active or
placebo NSAIDs which will be given to the participantBMC Musculoskeletal Disorders 2005, 6:57 http://www.biomedcentral.com/1471-2474/6/57
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along with a consumer medicine information sheet for
diclofenac. The participant's name will be fixed to the
medication. Placebo tablets with an identical shape and
colour (including dose form excipients and coating) are
dispensed making it impossible for the researchers or par-
ticipant to differentiate between the active and placebo
NSAIDs. The randomisation envelope will also contain a
second smaller envelope containing the participant's allo-
cation into active or placebo SMT. The researcher will give
this envelope to the treating physiotherapist to open after
the researcher has left. The researcher will therefore
remain blinded to allocation for the NSAIDs and SMT
arms. Treating physiotherapists can obviously not remain
blinded to SMT allocation however they will be trained to
respond identically to all patients regardless of treatment
group except for the treatment provided.
Patients will be allocated to one of four treatment groups
as follows:
• Control group (placebo NSAIDs and placebo SMT)
• NSAIDs group (active NSAIDs and placebo SMT)
• SMT group (placebo NSAIDs and active SMT)
• SMT and NSAIDs group (active NSAIDs and active SMT)
Treatments
All participants in the study will receive standard care
from their GP before baseline and allocation into a treat-
ment group. Standard care in this study will involve
advice and paracetamol (1 g four times daily), this being
the first line of care advocated in both national and inter-
national clinical practice guidelines. Advice will include
reassurance of a favourable prognosis and encouragement
to avoid bed rest and stay active. Paracetamol will be pre-
scribed at 4 gm per day (Two 500 mg tablets every 6 h).
Paracetamol is to be continued at this dosage for a maxi-
mum of four weeks. If subjects recover before four weeks
(zero or one out of ten pain for seven consecutive days)
paracetamol will be stopped. All participants will also
receive two follow up visits with their GP, one week and
two weeks after their initial visit. At follow up visits GPs
will reinforce the initial advice and ensure participants
have no adverse reactions to the treatments. GPs will
remain blinded to group allocation and instructed not to
ask about the physiotherapy management.
Participants allocated to receive active or placebo NSAIDs
(diclofenac) will be instructed to take them according to
an identical schedule. Dosage will be 50 mg bd taken with
food for a maximum of four weeks or until the participant
has recovered (zero or one out of ten pain for seven con-
secutive days).
Participants allocated to receive SMT will receive treat-
ment two or three times per week (at the therapist's discre-
tion) for a maximum of 12 treatments over four weeks. If
the subject recovers (zero or one out of ten pain for seven
consecutive days) before four weeks the SMT will be
stopped. Patients will receive spinal manipulative therapy
according to a treatment algorithm developed by the
researchers based on the views of expert clinicians and
researchers in the field (Additional file 1) [17-20]. The
algorithm permits and excludes certain physiotherapy
treatments. Consistent with contemporary best clinical
practice, the physiotherapist will adjust the treatment to
the clinical presentation of the patient rather than apply
the same treatment to all patients (as per normal clinical
practice). The algorithm however is sufficiently prescrip-
tive to allow replication and accurate description of the
trial treatment. All participants will be examined by the
physiotherapist who will take a standard history and per-
form a physical examination that will include assessment
of active range of lumbar spinal motion, routine tension
tests (straight leg raise, passive neck flexion and prone
knee bend), neurological examination (reflexes, muscle
strength, sensation) when indicated and the application
of manually applied postero-anteriorly directed forces to
all levels of the lumbar spine. Based on findings from the
examination the physiotherapist will initiate what they
consider to be an optimal program of SMT within the
guidelines of the study (Additional file 1).
SMT will be delivered by physiotherapists who have post-
graduate training in manipulative therapy and who regu-
larly use manipulative therapy in their clinical practice.
Participating physiotherapists will be supplied with docu-
mentation defining their role in the trial and will undergo
one hour of training from a researcher who is a physio-
therapist. These physiotherapists will have as minimum
training a Graduate Diploma in Manipulative Physiother-
apy and two years clinical experience using manipulative
therapy techniques.
Therapists will be asked to keep a record of the number of
times the participant attended for SMT and details of the
treatment including the techniques and dosage. These will
be used to ensure compliance with the protocol and to
help describe the treatment given in this study.
Placebo SMT will be prescribed using exactly the same
schedule as active SMT. The placebo therapy used will be
detuned ultrasound (US). The detuned US will be per-
formed in a manner that mimics real US around the area
involved for 5–12 minutes. Treatment sessions will last
for the same time as for active SMT (30–40 minutes for
the initial assessment and treatment and approximately
20 min for follow up sessions). Follow ups will include
reassessing the participant's history and physical examina-BMC Musculoskeletal Disorders 2005, 6:57 http://www.biomedcentral.com/1471-2474/6/57
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tion findings however no palpation of the spinal joints
will be performed after the initial assessment. A re-evalu-
ation of pain or range of motion will be done after the pla-
cebo treatment. In this way we will achieve close matching
of the active and inactive interventions in terms of treat-
ment duration and patient/therapist contact.
Patients will be asked not to seek other treatments for
their low back pain during the treatment period. In cases
where this is unavoidable a record of additional treat-
ments will be kept (and these patients may be excluded
from the per protocol but not intention to treat analysis
depending on the nature of the treatment). Several mech-
anisms will be used to ensure that the trial protocol is con-
sistently applied. Protocol manuals will be developed and
all involved researchers (general practitioners, manipula-
tive physiotherapists, trial manager and outcome asses-
sors) will be trained to ensure that screening, assessment,
random allocation and treatment procedures are con-
ducted according to protocol. An independent researcher
will monitor adherence to assessment, randomisation
and treatment procedures in a random group of partici-
pants.
After four weeks all interventions will cease and partici-
pants will be asked not to seek other treatment before the
three month follow-up if possible. Participants who do
have further treatment will be asked to record the type and
amount received.
Outcome measures
Outcome measures will be recorded by an assessor
blinded to group allocation. Outcome measures will be
collected using both a daily pain diary completed by the
participants and weekly phone follow-ups for the first
four weeks and at three months.
The primary outcome is the number of days to recovery,
with recovery defined in two ways. Firstly recovery is
defined as a pain score of 0 or 1 on a 0–10 pain scale
(numerical pain rating scale) that is maintained for seven
consecutive days. Secondly recovery is defined as the first
day that the patient has a pain score of 0–1 on a 0–10 pain
scale. To ensure a precise estimate of the time to recovery,
subjects will complete a daily pain diary (completed
either first thing in the morning or last thing at night
determined by the participant) until recovery. To mini-
mize potential for lost data pain scores from the diaries
will be read to the researcher at each of the phone follow
ups. The researcher will then transcribe these into a sec-
ond participant record. Diaries will be kept until the
patient has scored 0 or 1 out of 10 for seven consecutive
days or for a maximum of three months.
The secondary outcomes are pain (numerical pain rating
scale) [21], disability (Patient Specific Functional
Scale[16] and Roland Morris Disability Questionnaire
[15]), global perceived effect and satisfaction/beliefs
about treatment [22]. Secondary outcomes will be
recorded at baseline, 1 week, 2 weeks, 4 weeks and 3
months.
Compliance with physiotherapy will be recorded by the
treating physiotherapists. Compliance with the medica-
tions will be assessed by collecting unused medications at
the end of the treatment period (4 weeks).
Data analysis
Data will be analysed by a statistician who is blinded to
group status. The primary analyses will be by intention-to-
treat and we will restrict the number of analyses in order
to reduce the possibility of Type I errors. For primary out-
comes, a p value of <0.05 will be considered statistically
significant. For the secondary outcomes a p value of <0.01
will be considered significant.
For the primary outcome of days to reach recovery we will
use survival curves with a log-rank statistic to assess differ-
ences between groups [23] and, if required, Cox's regres-
sion to assess the effects of treatment (group) status on
hazard rates for time to recovery. In the primary analysis,
number needed to treat (NNT) and the 95% confidence
intervals to reach recovery in three months will also be
calculated.
For secondary outcomes we will use a mixed model with
group as a fixed factor. In these analyses, if there is a sig-
nificant difference in secondary outcomes between treat-
ment groups, we will conduct post-hoc analyses to inspect
differences in secondary outcome variables at 1, 2, and 4
weeks and 3 months. We will also test for any additive or
multiplicative effects between treatments on the outcome
variables
Sample size
Sample size was calculated using equations for survival
data. Two hundred and forty participants was determined
to provide 80% power to detect a 20% difference in recov-
ery rates between the control and intervention groups
with an alpha level of 0.05. These calculations were based
on a 50% recovery rate in the control group by three
months. These numbers are probably conservative and
based on results from our recent prognostic study of over
1000 subjects with acute low back pain. Higher rates of
recovery will increase the statistical power. We allowed for
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Conclusion
We have presented the rationale and design for an RCT
examining the effects of SMT and/or NSAIDs on patients
with significant acute low back pain. The primary out-
come will be days to recovery and secondary outcomes
include pain, disability and global perceived effect at 1
week, 2 weeks, 4 weeks and 3 months. The results of this
trial will be available in 2007.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
MH, CM, JL, AM, CC, RD, MS and JM were responsible for
the design of the study. All authors read and approved the
final manuscript.
Additional material
Acknowledgements
This project is funded by the National Health and Medical Research Council 
of Australia. The authors wish to thanks the participating GPs and physio-
therapists for their participation in this project.
References
1. Walker BF: The prevalence of low back pain: a systematic review of
the literature from 1966 to 1998.  Journal of Spinal Disorders 2000,
13:205-217.
2. Australian Institute of Health and Welfare: Australia's health 2000:
the seventh biennial health report of the Australian Institute
of Health and Welfare.  Canberra, AIHW; 2000. 
3. Pengel LHM, Herbert RD, Maher CG, Refshauge KM: Acute low
back pain: systematic review of its prognosis.  BMJ 2003,
327:323.
4. Koes BW, van Tulder MW, Ostelo R, Kim Burton A, Waddell G:
Clinical guidelines for the management of low back pain in
primary care: an international comparison.  Spine 2001,
26:2504-13; discussion 2513-4.
5. Australian Acute Musculoskeletal Pain Guidelines Group: Evidence-
Based Management of Acute Musculoskeletal Pain - A guide
for clinicians.  Bowen Hills, Australian Academic Press; 2003. 
6. Ferreira ML, Ferreira PH, Latimer J, Herbert R, Maher CG: Efficacy
of spinal manipulative therapy for low back pain of less than
three months' duration.  J Manipulative Physiol Ther 2003,
26:593-601.
7. Assendelft WJ, Morton S, Yu E, Suttorp M, Shekelle P: Spinal manip-
ulative therapy for low back pain. A meta-analysis of effec-
tiveness relative to other therapies.  Annals of Internal Medicine
2003, 138:871-881.
8. Cherkin D, Sherman KJ, Deyo R, Shekelle P: A review of the evi-
dence for the effectiveness, safety and cost of acupuncture,
massage therapy and spinal manipulation for back pain.
Annals of Internal Medicine 2003, 138:898-906.
9. Curtis P, Carey T, Evans P, Rowane M, Garrett J, Jackman A: Train-
ing primary care practitioners to give limited manual ther-
apy for low back pain.  Spine 2000, 25:2954-2961.
10. van Tulder MW, Scholten RJ, Koes BW, Deyo RA: Non-steroidal
anti-inflammatory drugs for low back pain.  Cochrane Database
Syst Rev 2000:CD000396.
11. Schattenkirchner M, Milachowski KA: A double-blind, multicen-
tre, randomised clinical trial comparing the efficacy and tol-
erability of aceclofenac with diclofenac resinate in patients
with acute low back pain.  Clin Rheumatol 2003, 22:127-135.
12. Dreiser RL, Marty M, Ionescu E, Gold M, Liu JH: Relief of acute low
back pain with diclofenac-K 12.5 mg tablets: a flexible dose,
ibuprofen 200 mg and placebo-controlled clinical trial.  Int J
Clin Pharmacol Ther 2003, 41:375-385.
13. de Vet HC, Heymans MW, Dunn KM, Pope DP, van der Beek AJ, Mac-
farlane GJ, Bouter LM, Croft PR: Episodes of low back pain: a pro-
posal for uniform definitions to be used in research.  Spine
2002, 27:2409-2416.
14. Pengel LHM, Refshauge KM, Maher CG: Responsiveness of pain,
disability, and physical impairment outcomes in patients
with low back pain.  Spine 2004, 29:879-883.
15. Roland M, Morris R: A study of the natural history of back pain.
Part I: development of a reliable and sensitive measure of
disability in low-back pain.  Spine 1983, 8:141-144.
16. Stratford P, Gill C, Westaway M, Binkley J: Assessing disability and
change on individual patients: a report of a patient specific
measure.  Physiotherapy Canada 1995, 47:258-263.
17. Maitland GD: Vertebral manipulation.  5th edition. London, But-
terworths; 1986. 
18. Grieve G: Mobilisation of the spine. Notes on examination,
assessment and clinical method.  4th edition. Edinburgh, Church-
ill Livingston; 1984. 
19. Jull G, Treleaven J, Versace G: Manual examination: is pain prov-
ocation a major cue for spinal dysfunction?  Australian Journal of
Physiotherapy 1994, 40:159-165.
20. Jull G, Treleaven J, Versace G: Examination of the articular sys-
tem.  In Grieve's modern manual therapy The Vertebral Column 2nd edi-
tion. Edited by: Boyling J PN. Edinburgh, Churchill Livingston; 1994. 
21. Farrar JT, Young JPJ, LaMoreaux L, Werth JL, Poole RM: Clinical
importance of changes in chronic pain intensity measured on
an 11-point numerical pain rating scale.[see comment].  Pain
2001, 94:149-158.
22. Long A, Donelson R, Fung T: Does it Matter Which Exercise? A
Randomised Control Trial of Exercise for Low Back Pain.
Spine 2004, 29:2593-2602.
23. Pocock SJ, Clayton TC, Altman DG: Survival plots of time-to-
event outcomes in clinical trials: good practice and pitfalls.
Lancet 2002, 359:1686-1689.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2474/6/57/prepub
Additional File 1
Description of active SMT.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2474-6-57-S1.doc]